Escala Medical awarded €5.5 million EIC funding to revolutionize pelvic organ prolapse treatment

Escala Medical Ltd., proudly announces its selection as a recipient of a €5.5 million in grant and equity investment from the European Innovation Council.  Escala is at the forefront of the pelvic organ prolapse (POP) treatment revolution.

Escala Medical’s breakthrough device brings incision-free pelvic organ prolapse treatment to women suffering from this widespread and debilitating condition, affecting approximately 50% of women worldwide. With a procedure that can be performed under local anesthesia in 5-8 minutes, Escala’s innovative approach addresses a significant market need. FDA-cleared, Escala’s revolutionary technology is now commercially available in the United States, marking a major milestone for the company.

Current surgical treatment options for POP are invasive and principally suitable for advanced stage prolapse. Until now, there have not been effective incision-free alternatives for women experiencing early-stage symptoms or for those patients who are not eligible for surgery.  Escala Medical is changing POP treatment with its much-needed solution for these underserved populations, while also providing a faster and easier solution for clinicians addressing patients with advanced stage POP.

This news was published in BioWorld.